NCT02237521View on ClinicalTrials.gov

The Effect of the Incretin Hormones on the Endocrine Pancreatic Function During Hyperglycemia in End-stage Renal Disease

CompletedOBSERVATIONAL
Enrollment

24

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

April 28, 2016

Study Completion Date

April 28, 2016

Conditions
End-stage Renal Disease
Interventions
OTHER

Eu- and hyperglycemic clamp

Eu- and hyperglycemic clamp with concomitant infusion of the natural occurring hormones glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP) or placebo along with stable glucose isotope infusion to measure the effects of the incretins.

OTHER

Arginine test

Bolus infusion of the natural occurring amino acid arginine to measure the ability to increase the secretion of insulin and glucagon

Trial Locations (1)

2100

Department of Nephrology, Rigshospitalet, Copenhagen

All Listed Sponsors
lead

Bo Feldt-Rasmussen

OTHER

NCT02237521 - The Effect of the Incretin Hormones on the Endocrine Pancreatic Function During Hyperglycemia in End-stage Renal Disease | Biotech Hunter | Biotech Hunter